Tendinopathy Market

Market Overview:

The 7 major tendinopathy markets reached a value of US$ 11.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.35% during 2024-2034.

The tendinopathy market has been comprehensively analyzed in IMARC's new report titled "Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tendinopathy refers to a group of conditions characterized by damage, degeneration, or inflammation of tendons, which are thick, fibrous cords that connect muscles to bones. The disease can affect any tendon in the body, but it commonly occurs in the shoulders, elbows, wrists, knees, hips, and ankles. The most common symptoms of this illness include pain, impaired function, tenderness, swelling, stiffness, reduced range of motion, etc. The pain associated with the ailment typically worsens with movement or activity involving the affected tendon. The diagnosis of this disorder relies on a detailed medical history, including information about symptoms, onset, and aggravating factors. A physical examination may be conducted to assess the afflicted region for any signs of inflammation or localized tenderness. The healthcare provider may further perform various diagnostic procedures, such as X-rays, magnetic resonance imaging, ultrasounds, etc., to evaluate real-time images of the tendons. In some cases, blood workups may be required to check for markers of inflammation, like C-reactive protein and erythrocyte sedimentation rate, to confirm a diagnosis among patients.

The increasing cases of biomechanical imbalances on account of improper training techniques during sports, poor posture, structural abnormalities, etc., are primarily driving the tendinopathy market. In addition to this, the rising incidences of various associated risk factors, such as trauma, injury, advancing age, certain systemic diseases, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen, that help to reduce pain and inflammation in individuals suffering from tendinopathy is further bolstering the market growth. Apart from this, the escalating utilization of platelet-rich plasma therapy, which involves injecting a concentrated solution of the patient's own platelets into the affected tendon to promote tissue healing, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of orthotic devices, such as braces, splints, shoe inserts, etc., since they can provide support and relieve stress, is also augmenting the market growth. Furthermore, the inflating demand for extracorporeal shockwave therapy that aids in stimulating blood flow and enhancing tissue regeneration is expected to drive the tendinopathy market during the forecast period. 

IMARC Group's new report provides an exhaustive analysis of the tendinopathy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for tendinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tendinopathy market in any manner.

Key Highlights:

• Tendinopathy represents 45% of musculoskeletal illnesses.
• Tendinopathy is most common among middle-aged adults.
• Children are less likely to develop tendinopathy because their growth plates and tendon insertions are more vulnerable to injury than their tendons, which are more elastic and durable.
• Tendinopathy is most typically induced by athletic activity. However, one-third of Achilles tendinopathy patients do not participate in sports.
• Non-athletes are more prone to upper extremity tendinopathy, which is typically work-related.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the tendinopathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the tendinopathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current tendinopathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the tendinopathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the tendinopathy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the tendinopathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of tendinopathy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of tendinopathy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of tendinopathy by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with tendinopathy across the seven major markets?
• What is the size of the tendinopathy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of tendinopathy?
• What will be the growth rate of patients across the seven major markets?
   

Tendinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for tendinopathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tendinopathy market?
• What are the key regulatory events related to the tendinopathy market?
• What is the structure of clinical trial landscape by status related to the tendinopathy market?
• What is the structure of clinical trial landscape by phase related to the tendinopathy market?
• What is the structure of clinical trial landscape by route of administration related to the tendinopathy market?